Coronavirus Infection - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Coronavirus Infection - Pipeline Review, H1 2016', provides an overview of the Coronavirus Infection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronavirus Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronavirus Infection and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection - The report reviews pipeline therapeutics for Coronavirus Infection by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Coronavirus Infection therapeutics and enlists all their major and minor projects - The report assesses Coronavirus Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Coronavirus Infection Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Coronavirus Infection Overview 7 Therapeutics Development 8 Pipeline Products for Coronavirus Infection - Overview 8 Pipeline Products for Coronavirus Infection - Comparative Analysis 9 Coronavirus Infection - Therapeutics under Development by Companies 10 Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 11 Coronavirus Infection - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Coronavirus Infection - Products under Development by Companies 15 Coronavirus Infection - Products under Investigation by Universities/Institutes 16 Coronavirus Infection - Companies Involved in Therapeutics Development 17 AstraZeneca Plc 17 Hemispherx Biopharma, Inc. 18 Humabs BioMed SA 19 Kineta, Inc. 20 NanoViricides, Inc. 21 Novavax, Inc. 22 Organic Vaccines 23 Phelix Therapeutics, LLC 24 Regeneron Pharmaceuticals, Inc. 25 Coronavirus Infection - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 coronavirus vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 coronavirus vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 FBR-001 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 interferon alfa-n3 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 interferon beta-1a - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 LCA-60 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 MERS-CoV Vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Middle East respiratory syndrome vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Monoclonal Antibodies for Middle East Respiratory Syndrome - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Monoclonal Antibody for Coronavirus Infection - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SAB-301 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecules for Viral Infections - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 SSYA-10001 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Coronavirus Infection - Recent Pipeline Updates 53 Coronavirus Infection - Dormant Projects 58 Coronavirus Infection - Product Development Milestones 59 Featured News & Press Releases 59 Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome 59 Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 59 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for Coronavirus Infection, H1 2016 8 Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Coronavirus Infection - Pipeline by AstraZeneca Plc, H1 2016 17 Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H1 2016 18 Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2016 19 Coronavirus Infection - Pipeline by Kineta, Inc., H1 2016 20 Coronavirus Infection - Pipeline by NanoViricides, Inc., H1 2016 21 Coronavirus Infection - Pipeline by Novavax, Inc., H1 2016 22 Coronavirus Infection - Pipeline by Organic Vaccines, H1 2016 23 Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H1 2016 24 Coronavirus Infection - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2016 53 Coronavirus Infection - Dormant Projects, H1 2016 58
List of Figures
Number of Products under Development for Coronavirus Infection, H1 2016 8 Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Targets, H1 2016 27 Number of Products by Stage and Targets, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 29 Number of Products by Stage and Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Molecule Types, H1 2016 33 Number of Products by Stage and Molecule Types, H1 2016 33
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmenRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.